Article: Metabolex Closes $8.6 Million Financing Round.

Article from:: PR Newswire
Article date:: November 5, 2009

Funds to Continue Advancement of Four Clinical Stage Candidates

HAYWARD, Calif., Nov. 5 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, today announced it had closed an additional $8.6 million in financing. Participating investors in this insider financing include: Alta Partners, Venrock, Versant Ventures, Bay City Capital, VantagePoint Venture Partners, Novo Ventures, Pictet, Next Chapter Holdings, Charter Ventures, Merlin Biomed, and Birchmere Ventures.

The company plans to use the funds to continue to advance development of its ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: Metabolex Announces Start of Phase 2 Trial of Its Novel ...
Business Wire; March 2, 2004 ; 700+ words ... ... lipid-lowering agent. "In Phase 3 studies, MBX-102's parent compound, halofenate ... the company plans to partner MBX-102 for Phase 3 development and commercialization. Results of the Phase 1 MBX-102 Study Investigators conducted ...

Article: Metabolex Begins Phase 2a, Proof-of-Concept Study for ...
PR Newswire; December 20, 2006 ; 700+ words ... ... candidates and drug discovery targets. The company has three clinical-stage compounds: metaglidasen (MBX- 102), in Phase 2/3; MBX-2044, in Phase 2a; and MBX-8025, being studied in dyslipidemia, which has completed Phase 1 studies. Both ...

Article: Metabolex Begins Phase 2 Trial of MBX-8025 for ...
PR Newswire; September 25, 2007 ; 700+ words ... ... announced today that it has begun a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high ... 102/JNJ 39659100, in Phase 2/3 testing; MBX-2044, in Phase 2a; and MBX-8025, being studied in dyslipidemia, now ...

Article: Metabolex Announces Positive Results From Phase 1a ...
PR Newswire; November 12, 2008 ; 700+ words ... ... our Phase 1a trial, we have advanced MBX-2982 into a Phase 1b study in which we are evaluating ... 39659100, which has completed three Phase 2 trials; MBX-2044, which has completed a Phase 2a trial; MBX-8025, which recently completed a ...

Article: Metabolex Announces Positive Phase 1 Clinical Trial ...
PR Newswire; October 13, 2009 ; 700+ words ... ... has recently completed two additional Phase 1 studies of MBX-2982 in subjects with pre-diabetes ... 39659100, which has completed three Phase 2 trials; MBX-2044, which has completed a Phase 2a trial; MBX-8025, which recently completed a ...

Article: Metabolex Announces Positive Results from Phase 2 Clinical ...
PR Newswire; November 18, 2008 ; 700+ words ... ... Medical Officer of Metabolex. "In this Phase 2 study, MBX-8025 clearly demonstrated robust improvement ... 39659100, which has completed three Phase 2 trials; MBX-2044, which has completed a Phase 2a trial; MBX-8025, which recently completed a ...

Article: Phase II trial of insulin sensitizer MBX-102 ...
Biotech Business Week; March 29, 2004 ; 700+ words ... ... announced the start of its phase II study of its investigational insulin sensitizer, MBX-102. The double ... lowering agent. "In phase III studies, MBX-102's parent compound ... company plans to partner MBX-102 for phase III development and commercialization ...

Article: Metabolex Announces Positive Results from Phase 2 Clinical ...
Obesity & Diabetes Week; December 1, 2008 ; 700+ words ... ... positive results from a Phase 2 clinical trial of MBX-8025. A summary of ... and Diabetes). The Phase 2 study was a randomized ... safety and efficacy of MBX-8025, both alone ... Metabolex. "In this Phase 2 study, MBX-8025 clearly demonstrated ...

See all results Or, try our Advanced Search

Research articles and archives from 6,500+ publications

Article: Metabolex Closes $8.6 Million Financing Round.

Related newspaper, magazine, and journal articles:

Find articles, research, and archives